# US 2020/0390823 A1 · Free-standing, transferrable vascular networks via guided self-assembly and use in cell replacement therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390823 A1
- Document ID: US20200390823A1
- Status: Published application
- Kind: A1
- Application number: 16/968,392
- Filed: 2019-02-07
- Published: 2020-12-17
- Earliest claimed: 2018-02-07
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Minglin MA; Wei SONG; Alan CHIU
- Web page: https://patentgrep.com/patent/US20200390823A1

## CPC

- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A01N 1/128: Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/33: Fibroblasts
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS

## Abstract

The present invention relates to a vascularized therapeutic delivery system. This system includes a preparation of cells encapsulated by a biological support material and a microvascular mesh that at least partially surrounds the biological support material encapsulating the preparation of cells, where the microvascular mesh includes a network of continuous interconnected tubular structures defined by endothelial cells and an extracellular matrix scaffold. Also disclosed are methods for delivering a therapeutic agent to a subject using the vascularized therapeutic delivery system and methods of producing such a vascularized therapeutic delivery system.

## Claims

### Claim 1

A vascularized therapeutic delivery system, said system comprising:
a preparation of cells encapsulated by a biological support material and
a microvascular mesh that at least partially surrounds the biological support material encapsulating the preparation of cells, wherein the microvascular mesh comprises a network of continuous interconnected tubular structures defined by endothelial cells and an extracellular matrix scaffold.

### Claim 2 (depends on 1)

The vascularized therapeutic delivery system of claim 1, wherein the preparation of cells is a preparation of any one or more of endothelial cells, smooth muscle cells, cardiac muscle cells, cardiac myocytes, epithelial cells, urothelial cells, fibroblasts, myoblasts, chondrocytes, chondroblasts, osteoblasts, keratinocytes, hepatocytes, renal cells, pulmonary cells, bile duct cells, pancreatic islet cells, thyroid cells, parathyroid cells, adrenal cells, hypothalamic cells, pituitary cells, ovarian cells, testicular cells, salivary gland cells, adipocytes, embryonic stem cells, adult stem cells, induced pluripotent stem cells, mesenchymal stem cells, neuronal cells, astrocytes, oligodendrocytes, hematopoietic cells, and any precursor or progenitor cell thereof.

### Claim 3 (depends on 1, 2)

The vascularized therapeutic delivery system of claim 1 or claim 2, wherein the preparation of cells is a preparation of cells engineered to recombinantly express a therapeutic agent.

### Claim 4 (depends on 1, 2, 3)

The vascularized therapeutic delivery system of any one of claims 1-3, wherein the preparation of cells is a preparation of pancreatic islet cells.

### Claim 5 (depends on 1, 2, 3, 4)

The vascularized therapeutic delivery system of any one of claims 1-4, wherein the biological support material is a synthetic polymer material selected from the group consisting of polycaprolactone, polylactic acid, polyglycolide, poly(lactic-co-glycolic) acid, polytetrafluoroethylene, nylon, polydimethylsiloxane, polyvinylchloride, polyvinylidene fluoride, polyurethane isocyanates, alginate, cellulose acetate, cellulose nitrate, polysulfone, polyether sulfones, polystyrene, polyurethane, polyvinyl alcohols, polyvinylidenes, polyvinyl chloride copolymers, polyacrylonitrile, poly(acrylonitrile/covinyl chloride), polyamides, polymethylmethacrylate, polyacrylates, polyphosphazenes, polyethylene oxide, and mixtures thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The vascularized therapeutic delivery system of any one of claims 1-5, wherein the biological support material is a material selected from the group consisting of hydrogel, collagen, hyaluronate, fibrin, fibroin, alginate, agarose, chitosan, bacterial cellulose, elastin, keratin, and combinations thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6, 7)

The vascularized therapeutic delivery system of any one of claims 1-7, wherein the extracellular matrix scaffold is comprised of an extracellular matrix component selected from fibronectin, laminin, heparin, collagen, glycosaminoglycan, proteoglycan, elastin, fibrin, fibroin, and combinations thereof.

### Claim 8 (depends on 7)

The vascularized therapeutic delivery system of claim 7, wherein the extracellular matrix scaffold comprises fibrin.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The vascularized therapeutic delivery system of any one of claims 1-8, wherein the tubular structures of the microvascular mesh have a diameter of about 15 μm to about 200 μm.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The vascularized therapeutic delivery system of any one of claims 1-9, wherein the tubular structures of the microvascular mesh are further defined by one or more type of support cell.

### Claim 11 (depends on 10)

The vascularized therapeutic delivery system of claim 10, wherein the one or more type of support cell is selected from fibroblasts, smooth muscle cells, mesenchymal stem cells, and perivascular cells.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The vascularized therapeutic delivery system of any one of claims 1-11, wherein one or more of the tubular structures are filled with extracellular matrix scaffold.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The vascularized therapeutic delivery system of any one of claims 1-11 wherein one or more of the tubular structures comprise a lumen.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The vascularized therapeutic delivery system of any one of claims 1-13, wherein the endothelial cells are human umbilical vein endothelial cells (HUVEC).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The vascularized therapeutic delivery system of any one of claims 1-14, wherein the endothelial cells are derived from induced pluripotent stem cells.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The vascularized therapeutic delivery system of any one of claims 1-15, wherein the microvascular mesh has a plurality of openings, wherein each opening in the mesh ranges in size from about 20 μm to about 1000 μm.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The vascularized therapeutic delivery system of any one of claims 1-16, wherein the microvascular mesh has a density of openings ranging from 1 to 100 openings/mm2.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The vascularized therapeutic delivery system of any one of claims 1-17, wherein mesh openings have a triangular, quadrilateral, pentagon, hexagon, heptagon, octagon, nonagon, decagon, circular, or microcapillary geometry.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The vascularize therapeutic delivery system of any one of claim 1-17, wherein the network of tubular structures and openings of the microvascular mesh are organized in a web pattern.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method for delivering a therapeutic agent to a subject, said method comprising:
selecting a subject in need of a therapeutic agent;
providing the vascularized therapeutic delivery system of any one of claims 1-19; and
implanting the vascularized therapeutic delivery system into a region of the selected subject suitable for delivering the therapeutic agent.

### Claim 21 (depends on 20)

The method of claim 20, wherein the vascularized therapeutic delivery system is implanted into a subcutaneous region of the selected subject.

### Claim 22 (depends on 20)

The method of claim 20, wherein the therapeutic agent comprises the preparation of encapsulated cells of the vascularized therapeutic delivery system.

### Claim 23 (depends on 20)

The method claim 20, wherein the therapeutic agent is released from the preparation of encapsulated cells of the vascularized therapeutic delivery system.

### Claim 24 (depends on 20)

The method of claim 20, wherein the microvascular mesh of the vascularized therapeutic delivery system comprises endothelial cells obtained from the selected subject.

### Claim 25 (depends on 20)

The method of claim 20, wherein the subject is a human.

### Claim 26 (depends on 20)

The method of claim 20 further comprising:
retrieving and replacing the vascularized therapeutic delivery system in the selected subject.

### Claim 27

A method of producing a vascularized therapeutic delivery system, said method comprising:
providing a monolithic substrate comprising a planar surface interrupted by a plurality of micropillars;
applying endothelial cells suspended in an extracellular matrix material to the planar surface of the monolithic substrate;
culturing the suspended endothelial cells under conditions effective for the endothelial cells to organized into a microvascular mesh, wherein said microvascular mesh comprises a network of continuous interconnected tubular structures defined by the endothelial cells and extracellular matrix material;
transferring the microvascular mesh to an outer surface of an implantable cell delivery construct comprising a preparation of cells, thereby producing the vascularized therapeutic delivery system.

### Claim 28 (depends on 27)

The method of claim 27, wherein the microvascular mesh has openings, wherein said openings in the mesh range in size from 20 μm to 1000 μm.

### Claim 29 (depends on 27, 28)

The method of claim 27 or claim 28, wherein the microvascular mesh has a density of openings ranging from 1 to 100 openings/mm2.

### Claim 30 (depends on 27, 28, 29)

The method of any one of claims 27-29, wherein the micropillars are sized and spatially arranged on the surface of the substrate in a manner effective to define mesh opening geometry.

### Claim 31 (depends on 30)

The method of any one of claim 30, wherein the mesh openings have a triangular, quadrilateral, pentagon, hexagon, heptagon, octagon, nonagon, decagon, circular, or microcapillary geometry.

### Claim 32 (depends on 27, 28, 29, 30)

The method of any one of claims 27-30, wherein the network of tubular structures and openings of the microvascular mesh are organized in a web pattern.

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

The method of any one of claims 27-32, wherein each of the plurality of micropillars has a diameter of about 100 μm to about 400 μm.

### Claim 34 (depends on 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 27-33, wherein distance between adjacent micropillars on the surface of the substrate is about 50 μm to about 500 μm.

### Claim 35 (depends on 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 27-34, wherein of the tubular structures of the microvascular mesh have an internal diameter of about 15 μm to about 200 μm.

### Claim 36 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 27-35, wherein the endothelial cells are human umbilical vein endothelial cells (HUVEC).

### Claim 37 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method any one of claims 27-36, wherein the endothelial cells are derived from induced pluripotent stem cells.

### Claim 38 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 27-37, wherein one or more type of support cell is suspended along with the endothelial cells in the extracellular matrix material for said applying, and said tubular structures are further defined by said one or more type of support cell.

### Claim 39 (depends on 38)

The method of claim 38, wherein the one or more type of support cell is selected from fibroblasts, mesenchymal stem cells, smooth muscle cells, and perivascular cells.

### Claim 40 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 27-39, wherein the extracellular matrix material is comprised of an extracellular matrix component selected from fibronectin, laminin, heparin, collagen, glycosaminoglycan, proteoglycan, elastin, fibrin, fibroin, and combinations thereof.

### Claim 41 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 27-40, wherein the preparation of cells in the implantable cell delivery construct is a preparation of any one or more of smooth muscle cells, endothelial cells, cardiac muscle cells, cardiac myocytes, epithelial cells, urothelial cells, fibroblasts, myoblasts, chondrocytes, chondroblasts, osteoblasts, keratinocytes, hepatocytes, bile duct cells, pancreatic islet cells, thyroid cells, parathyroid cells, adrenal cells, hypothalamic cells, pituitary cells, ovarian cells, testicular cells, salivary gland cells, adipocytes, embryonic stem cells, induced pluripotent stem cells, adult stem cells, mesenchymal stem cells, neural cells, astrocytes, oligodendrocytes, hematopoietic cells, and any precursor or progenitor cell thereof.

### Claim 42 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 27-41, wherein the preparation of cells in the implantable cell delivery construct is a preparation of cells engineered to recombinantly express a therapeutic agent.

### Claim 43 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 27-42 further comprising:
stacking two or more vascularized therapeutic delivery systems together vertically and
encapsulating said stacked vascularized therapeutic delivery systems in an angiogenic support material.

### Claim 44 (depends on 43)

The method of claim 43, wherein the angiogenic support material is selected from hydrogel, collagen, hyaluronate, fibrin, fibroin, alginate, agarose, chitosan, bacterial cellulose, elastin, keratin, and combinations thereof.

### Claim 45 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 27-44 further comprising:
selecting a subject in need of a therapeutic agent and
implanting the vascularized therapeutic delivery system into said subject.
